Signature biomarker analysis for prediction of skin sensitizers using a cell-based in vitro alternative to animal experimentation

Henrik Johansson, Ann-Sofie Albrekt, Carl A.K. Borrebaeck, Malin Lindstedt Department of Immunotechnology, Lund University, BMC D13, 21184 Lund, Sweden Introduction Allergic contact dermatitis is an inflammatory skin disease caused by immunological responses towards chemical haptens. Current test of sensitizing chemicals rely on animal experimentation. New legislations on the registration and use of chemicals within pharmaceutical […]

Henrik Johansson, Ann-Sofie Albrekt, Carl A.K. Borrebaeck, Malin Lindstedt
Department of Immunotechnology, Lund University, BMC D13, 21184 Lund, Sweden

Introduction
Allergic contact dermatitis is an inflammatory skin disease caused by immunological responses towards chemical haptens. Current test of sensitizing chemicals rely on animal experimentation. New legislations on the registration and use of chemicals within pharmaceutical and cosmetic industries have stimulated significant research efforts to develop alternative, human cell-based assays for the prediction of sensitization.
We have developed a novel cell-based assay for the prediction of sensitizing chemicals, based on differentially regulated transcripts in the myeloid cell-line MUTZ-3.

 

Conclusions
We have identified a biomarker signature with accurate predictive power, which represents a compelling readout for an in vitro assay useful for the identification of human sensitizing chemicals. The biomarker signature include transcripts involved in relevant biological pathways, such as oxidative stress and xenobiotoic induced responses, which sheds light on the molecular interactions involved in the process of sensitization.

Poster:

Signature biomarker analysis for prediction of skin sensitizers using a cell-based in vitro alternative to animal experimentation_EAACI 2011 LTH_p

 

Pattern rules: biomarker signatures for sensitization as an alternative to animal testing

Biomarkers in Medicine, December 2011 ,Vol. 5, No. 6 , Pages 809-811 (doi: 10.2217/bmm.11.82) Lindstedt M., Borrebaeck C.A.K. “Identification of relevant endpoints and biomarkers is essensial for development of alternative assays predicting sensitisation. Omics-based techniques have recently generated very promising biomarker patterns, as well as pathways, which will be used in the identification of sensitising agents” […]
Biomarkers in Medicine, December 2011 ,Vol. 5, No. 6 , Pages 809-811
(doi: 10.2217/bmm.11.82)
Lindstedt M., Borrebaeck C.A.K.
“Identification of relevant endpoints and biomarkers is essensial for development of alternative assays predicting sensitisation. Omics-based techniques have recently generated very promising biomarker patterns, as well as pathways, which will be used in the identification of sensitising agents”